美股异动丨Capricor暴涨534%，公布3期试验积极结果

Core Insights - Capricor Therapeutics Inc. (CAPR) experienced a significant stock surge of 534.75%, leading to a temporary trading halt due to excessive volatility [1] - The surge was driven by the announcement of positive topline results from the Phase 3 HOPE-3 trial evaluating the company's DMD (Duchenne Muscular Dystrophy) Dexamethasone cell therapy, which met its primary endpoint and key secondary cardiac endpoints [1] Company Summary - Capricor Therapeutics Inc. is focused on developing innovative therapies for rare diseases, particularly DMD [1] - The successful results from the HOPE-3 trial represent a critical milestone for the company, potentially enhancing its market position and investor interest [1]